Figure 1.
Long-term outcomes of patients treated with CD19 CAR T-cell therapy with JCAR014. (A) DOR of patients who were in CR or PR by iwCLL criteria on day +28. (B) PFS and (C) OS of all patients who received CAR T-cell infusion.
Long-term outcomes of patients treated with CD19 CAR T-cell therapy with JCAR014. (A) DOR of patients who were in CR or PR by iwCLL criteria on day +28. (B) PFS and (C) OS of all patients who received CAR T-cell infusion.
